COVAX Facility – Providing access to COVID-19 vaccines

COVAX Facility

The COVAX Facility is a global cooperation aimed at providing safe, equitable access to COVID-19 vaccines. Both the Philippines and Canada are participating in the COVAX Facility.

COVAX is the world’s best hope of ending the COVID-19 pandemic, having the world’s largest and most diverse portfolio of vaccines.

At the start of the COVID-19 pandemic, global leaders realized that the world didn’t just need vaccines for just the countries that could afford to pay for them, but also access to countries that couldn’t.

Leaders from around the world called for a way to accelerate the development and manufacture of vaccines that would guarantee fast and fair access for all countries. The result of this global call-to-action is the COVAX Facility.


COVAX is a global solution to the COVID-19 pandemic, ensuring that countries from all over the world will get access to vaccines when they become available.

COVAX is coordinated by GAVI, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO.

The Access to COVID-19 Tools (ACT) Accelerator was launched by the World Health Organization (WHO), the European Union (EU) and France. The ACT Accelerator brings governments, international health organizations, pharmaceutical companies, scientists and philanthropists to find innovative ways to provide access to diagnostic tools, treatment and vaccines.

The platform will support research, development and manufacturing of COVID-19 vaccines. Once developed, all participating countries will have access to vaccines.

COVAX aims to have more than 2 billion doses of COVID-19 vaccines available by the end of 2021, enough to protect frontline workers and the most vulnerable members of society.

COVAX will provide lower-income countries, as well as countries with no established contracts with pharmaceutical companies, with access to COVID-19 vaccines once available.

78 self-financing countries and 92 funded countries have so far confirmed their interest in joining the COVX Facility.


The world needs COVAX because without it, there’s a real chance that most countries will not be protected against COVID-19.

COVAX will help increase the chances of manufacturing vaccines in enough quantities to end the pandemic, while providing equitable access to countries that would otherwise be unable to afford them.

With more than 170 vaccine candidates currently in development, only 7% of these candidates are likely to move past the preclinical trial stage. Of these, only 20% make it past clinical trials.

COVAX has put together the largest and most diverse portfolio of COVID-19 vaccines, nine of which are currently being evaluated and another nine currently in development.

Countries that are participating in the COVAX Facility will have access to safe and effective vaccines. Self-financing countries will have a guaranteed number of doses, depending on the amount contributed, while funded countries will receive enough doses to vaccinate up to 20% of their population.

Allocation to funded countries will be determined by the amount of vaccines manufactured, and will increase as more supply is made available.

Gavi has also created the Gavi COVAX Advance Market Commitment (AMC) which will provide further support to lower-income countries. Separate from the COVAX Facility, the COVAX AMC is funded through Official Development Assistance (ODA) and private contributions.

The COVAX AMC has so far raised USD700 million of its USD2 billion target.


After successfully completing clinical trials and receiving regulatory approval, vaccines will be allocated to both self-financing and funded countries at the same rate, proportional to their total population.

For more information about the COVAX Facility, click here. is NOT affiliated with the Government of Canada, the Philippine Government, or any Philippine recruitment agencies or Canadian immigration consultants or lawyers.

All content on is for informational purposes only. makes no representations to the accuracy or completeness of any information on this site or any links found therein. will not be liable for any error or omission, nor for the availability of the information.

Leave a Reply